GSK 2586881

Drug Profile

GSK 2586881

Alternative Names: 2586881; APN-01; rhACE2

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Apeiron Biologics
  • Developer Apeiron Biologics; GlaxoSmithKline
  • Class Antihypertensives; Antineoplastics; Recombinant proteins
  • Mechanism of Action ACE stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute lung injury; Adult respiratory distress syndrome
  • No development reported Cancer; Diabetic nephropathies; Heart failure; Hypertension; Myocardial infarction

Most Recent Events

  • 22 Dec 2016 GlaxoSmithKline plans a phase I pharmacodynamics trial in Healthy volunteers in Germany (IV, Infusion) (NCT03000686)
  • 20 Jul 2015 Phase-II development is ongoing for Acute lung injury and Acute respiratory distress syndrome in Canada and USA
  • 01 Oct 2014 GlaxoSmithKline completes a phase II clinical trial in Acute lung injury and Acute respiratory distress syndrome in Canada and USA (IV) (NCT01597635)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top